WINTON GROUP Ltd acquired a new stake in Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 15,085 shares of the company’s stock, valued at approximately $459,000.
A number of other large investors also recently modified their holdings of the company. Envestnet Asset Management Inc. increased its position in shares of Meridian Bioscience by 0.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 41,308 shares of the company’s stock valued at $1,257,000 after purchasing an additional 341 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Meridian Bioscience in the 2nd quarter valued at $2,668,000. Texas Permanent School Fund boosted its holdings in shares of Meridian Bioscience by 2.0% in the 2nd quarter. Texas Permanent School Fund now owns 31,495 shares of the company’s stock valued at $958,000 after buying an additional 626 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Meridian Bioscience by 6.0% in the 2nd quarter. Arizona State Retirement System now owns 11,800 shares of the company’s stock valued at $359,000 after buying an additional 664 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of Meridian Bioscience by 6.1% in the 1st quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company’s stock valued at $464,000 after buying an additional 940 shares in the last quarter. 93.65% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Saturday.
Meridian Bioscience Stock Up 0.3 %
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.